HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY
HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY is a public limited company registered in England and Wales under company number 05557934. It was incorporated on 8 September 2005, and its registration status with Companies House is currently recorded as active. The company’s registered office is at 10 Portman Square, London W1H 6AZ.
HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY is the ultimate UK holding company and listed parent of the Hikma group, a multinational pharmaceutical business whose origins trace to a pharmaceutical manufacturer founded in Amman, Jordan, in 1978. The present public limited company was established in 2005 as the listing vehicle when the group’s shares were admitted to trading on the London Stock Exchange. Ordinary shares of HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY trade under the ticker HIK, and the company is a constituent of the FTSE 100 index.
Through its subsidiaries, the group develops, manufactures and markets a broad portfolio of generic and branded pharmaceutical products, organised principally around three business lines: Injectables, Branded medicines and Hikma Rx, the group’s US generics business. Products span therapeutic areas including cardiovascular, respiratory, oncology, gastrointestinal and central nervous system treatments, supplied to hospitals, pharmacies and healthcare providers across the Middle East and North Africa, the United States, Europe and other international markets.
For the financial year ended 31 December 2025, Hikma reported consolidated Group revenue of $3,349 million, an increase of 7% on the prior year, and core operating profit of $741 million, up 3%. These figures are reported on a consolidated Group basis and reflect the combined trading of the subsidiaries of HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY rather than the holding company alone. The Group employed more than 9,400 people in the 2025 financial year.
In its 2025 results commentary, Hikma reported that it had become the largest pharmaceutical company in the Middle East and North Africa region by sales during 2025, having ranked second in the region in 2024. Group research and development spend increased by 18% year-on-year, supporting 48 product submissions and 43 product launches.
As the ultimate parent and primary listed entity, HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY functions principally as a holding and reporting company; its own separate-entity trading activity should not be inferred from the Group operating figures reported above.
- Company fundamentals
- Corporate linkage & group structures
- Digitized company financials
- Firmographics — websites, social profiles, revenue and employee estimates
Shareholders
5
Shareholders of Hikma Pharmaceuticals Public Limited Company
Hikma Pharmaceuticals Public Limited Company is listed on the London Stock Exchange (ticker: HIK) and forms part of the FTSE 100 index. As a UK issuer with voting shares admitted to trading on a regulated market, the company does not maintain a statutory register of persons with significant control; instead, holders of notifiable interests must disclose threshold crossings under the UK Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.
The largest disclosed holding is that of the Darhold Concert Party, a group of shareholders connected to the company’s founding Darwazah family. According to Hikma’s own Rule 9 Waiver FAQs document, the Darhold Concert Party held 27.22% of Hikma’s total issued share capital and 28.80% of total voting rights as at the date of the company’s 2025 AGM Notice (19 March 2025). Darhold Limited is the vehicle through which this concert party holds its interest.
The most recent individual substantial-shareholder notification identified is Wellington Management Group LLP, which notified an increase in its holding to 5.10% of voting rights (5.05% held directly through shares and 0.05% through financial instruments), following a threshold crossing on 28 August 2026, disclosed on 1 September 2026.
Beyond these disclosed notifiable interests, Hikma’s shareholder base also includes numerous institutional and index-fund holders. The available information is best described as major shareholders only: it captures shareholders who have crossed statutory notification thresholds, not a complete register of all shareholders.
Ultimate beneficial ownership
No single natural person is identified by an authoritative source as holding a calculated effective ownership percentage in Hikma Pharmaceuticals Public Limited Company. The Darhold Concert Party’s combined 27.22% / 28.80% stake is held collectively by multiple members of the Darwazah family. Per Hikma’s own disclosure, each of Moh’d T. M. Darwazah, May Samih T. Darwazah, Bashir Yusuf Moh’d Al-Alami, Hana Samih Darwazah, Areej Samir Abdel Razzaq Qutob and Nirah S A Qutob individually holds less than 5% of the voting rights of Darhold Limited itself. Because the ownership chain from any single individual through Darhold Limited to Hikma is not disclosed at an individual level, no calculated effective UBO percentage can be reliably stated for any one person.
Data availability
Shareholder information is major shareholders only: the UK’s disclosure regime reveals holders that cross notification thresholds rather than a full shareholder register, and Hikma is exempt from PSC disclosure because its shares trade on a UK-regulated market. The figures above are dated between 19 March 2025 (Darhold Concert Party) and 1 September 2026 (Wellington Management Group LLP) and should not be read as a single snapshot.
Sources
- Hikma Pharmaceuticals PLC, Rule 9 Waiver FAQs — https://www.hikma.com/media/w4jjlnby/7-r9-waiver-faqs.pdf — retrieved 16 September 2026
- Investegate, RNS "Holding(s) in Company" (Wellington Management Group LLP) — https://www.investegate.co.uk/announcement/rns/hikma-pharmaceuticals–hik/holding-s-in-company/9752329 — published 1 September 2026, retrieved 16 September 2026
- Companies House, persons with significant control statement — https://find-and-update.company-information.service.gov.uk/company/05557934/persons-with-significant-control — retrieved 16 September 2026
Registry feed — rows exactly as filed with Companies House, including entries the profile above does not cover.
| Shareholder | Type | Holding | Source Document |
|---|---|---|---|
| VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund | 17.5% | Companies House | |
| iShares Trust-iShares MSCI EAFE ETF | 4.5% | Companies House | |
| American Century ETF Trust-Avantis International Small Cap Value ETF | 4.4% | Companies House | |
| iShares Trust-iShares MSCI EAFE Value ETF | 3.6% | Companies House | |
| iShares Trust-iShares MSCI EAFE Value ETF | 3.6% | Companies House |
Officers
29
Directors and officers of Hikma Pharmaceuticals Public Limited Company
According to Companies House, HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY currently has 10 active directors and 1 active company secretary. The board includes members of the founding Darwazah family, Said Samih Darwazah (appointed 1 July 2007) and Mazen Samih Darwazeh (appointed 8 September 2005), alongside other executive and non-executive directors. The most recent board appointments on record are Tobias Hannes Hestler, effective 7 August 2026, and Khalid Walid Hussni Nabilsi, effective 15 December 2025. Helen Middlemist has served as company secretary since 1 January 2024. All current officers share a correspondence address of 10 Portman Square, London, W1H 6AZ, which is a registered service address and not represented here as any individual’s residential address. This overview reflects the Companies House record retrieved on 16 September 2026 and may not include appointments made after that date.
Recent officer changes
- New appointment: Tobias Hannes Hestler appointed Director, effective 7 August 2026 (Companies House).
- New appointment: Khalid Walid Hussni Nabilsi appointed Director, effective 15 December 2025 (Companies House).
- New appointment: Helen Middlemist appointed Company Secretary, effective 1 January 2024 (Companies House).
Data availability
Companies House discloses nationality and country of residence for individual directors of UK companies; both fields are shown for active directors where officially disclosed, and neither was inferred from a person’s name or correspondence address. Historical (resigned) officers also exist on the public record but are not repeated in full here; only the most recent changes are listed above.
Sources
- Companies House, officers filing — https://find-and-update.company-information.service.gov.uk/company/05557934/officers — retrieved 16 September 2026
- Companies House, company overview — https://find-and-update.company-information.service.gov.uk/company/05557934 — retrieved 16 September 2026
Registry feed — rows exactly as filed with Companies House, including entries the profile above does not cover.
Group Structure
Group structure of Hikma Pharmaceuticals Public Limited Company
Hikma Pharmaceuticals Public Limited Company is the ultimate and top-listed parent of the Hikma group. It is the entity admitted to trading on the London Stock Exchange (ticker: HIK, FTSE 100), and no source reviewed identifies any further parent above it. UK Companies House records confirm that Hikma Pharmaceuticals Public Limited Company is registered as the person with significant control of Hikma UK Limited (company number 05497478), holding 75% or more of that company’s shares and voting rights, with effect from 4 January 2021. This interest was previously held via two other UK entities, Hikma Holdings (UK) Limited and Hikma Acquisitions (UK) Limited, both of which ceased to hold this control in 2021. Beyond this confirmed direct subsidiary, Zavia.ai’s corporate-linkage dataset lists a substantially larger group of entities associated with the Hikma name across the UK, Germany, the Netherlands, Spain, Portugal, Italy, Croatia, Tunisia, Saudi Arabia, Jordan, the United States, Switzerland, Canada, the United Arab Emirates and Morocco; these additional relationships were not independently confirmed against an official Companies House PSC filing, annual report "related undertakings" note or equivalent registry source in this research pass and should be treated as unverified leads rather than confirmed corporate links.
Verified corporate relationships
| Entity | Country | Registration number | Relationship | Ownership | Status | Information date |
|---|---|---|---|---|---|---|
| Hikma UK Limited | GB | 05497478 | Direct subsidiary | 75% or more of shares and voting rights | Active | 4 January 2021 |
Recent structural changes
- Change of control notification: Hikma Pharmaceuticals Public Limited Company replaced Hikma Acquisitions (UK) Limited as the registered person with significant control of Hikma UK Limited, effective 4 January 2021 (Companies House).
Data availability
Group-structure information for Hikma Pharmaceuticals Public Limited Company is partial: the parent-level position and one direct UK subsidiary relationship are confirmed via Companies House PSC filings, but the wider international subsidiary network referenced in Zavia.ai’s dataset was not independently verified against official filings in this update and is not presented as confirmed.
Sources
- Companies House, persons with significant control for Hikma UK Limited — https://find-and-update.company-information.service.gov.uk/company/05497478/persons-with-significant-control — retrieved 16 September 2026
- Companies House, company overview for Hikma Pharmaceuticals Public Limited Company — https://find-and-update.company-information.service.gov.uk/company/05557934 — retrieved 16 September 2026
Registry feed — rows exactly as filed with Companies House, including entries the profile above does not cover.
HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY
United Kingdom
Get complete shareholder and officer records, ultimate beneficial owner resolution, and ongoing ownership monitoring.
Frequently Asked Questions
What does HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY do?
Hikma Pharmaceuticals Public Limited Company is the UK-listed holding company of the Hikma pharmaceutical group, which develops, manufactures and markets generic and branded medicines, including injectables, through its Injectables, Branded and Hikma Rx business lines.
Who owns HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY?
The Darhold Concert Party, linked to the founding Darwazah family, held 27.22% of issued share capital and 28.80% of voting rights as at the 2025 AGM Notice (19 March 2025); Wellington Management Group LLP held 5.10% of voting rights as notified on 1 September 2026.
Who is HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY's UBO (Ultimate Beneficial Owner)?
No single individual is confirmed as an ultimate beneficial owner with a calculated effective percentage; the Darhold Concert Party's stake is held collectively by several Darwazah family members, each holding less than 5% of Darhold Limited's own voting rights.
What is HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY's company registration number?
HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY's registration number is 05557934, filed with Companies House in United Kingdom. Its current status on the register is active.
Is HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY still an active company?
HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY's status on Companies House is listed as active.
When was HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY incorporated?
HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY was incorporated on 8 September 2005, according to Companies House.
What is HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY's registered address?
The registered address on file for HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY is London, United Kingdom.
What legal structure is HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY registered as?
HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY is registered as a Public Limited Company in United Kingdom.
What is HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY's revenue?
Hikma reported consolidated Group revenue of $3,349 million for the financial year ended 31 December 2025, up 7% year-on-year, with core operating profit of $741 million.
Is HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY listed on a stock exchange?
Hikma Pharmaceuticals is listed on the London Stock Exchange under the ticker HIK and is a constituent of the FTSE 100 index.
Who are the officers/directors of HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY?
Companies House records 10 active directors and 1 active company secretary (Helen Middlemist, since 1 January 2024), including Darwazah family directors Said Samih Darwazah and Mazen Samih Darwazeh; the most recent director appointment is Tobias Hannes Hestler, effective 7 August 2026.
Does HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY have a parent company or subsidiaries?
Hikma Pharmaceuticals Public Limited Company is the ultimate listed parent of the Hikma group and is confirmed by Companies House as holding 75% or more of the shares and voting rights of Hikma UK Limited since 4 January 2021.
Can Zavia monitor changes to HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY's ownership over time?
This profile reflects a point-in-time snapshot from Companies House. Zavia's monitoring API can track changes to HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY's registered shareholders, officers, and group structure going forward, flagging updates as they're filed rather than requiring a manual recheck.
Can I access HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY's data through an API?
Yes. Zavia's API connects directly to official government ownership registries across 195 countries and territories, including United Kingdom, so records like HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY's registration, shareholder, UBO, and group-structure data can be queried programmatically instead of viewed one page at a time.
Where does this company information come from, and how current is it?
This record is sourced directly from Companies House and was last synced on 15 September 2026.